264 results Stibbe advises Lundbeck Stibbe advised Lundbeck on the acquisition of Prexton Therapeutics BV for an amount of up to EUR 905 million. Stibbe advises Aedifica Stibbe advised Aedifica on the acquisition of a healthcare residence for the elderly in Franeker (Friesland). Stibbe advises SleepScore Labs Stibbe advised SleepScore Labs on the acquisition of Sleep.ai, a Netherlands-based digital health company. Stibbe advises Aedifica Stibbe's Real Estate Transaction Group advised Aedifica NV, a Belgian listed company investing in healthcare real estate, on the further expansion of its portfolio in the Netherlands. Anya Murphy Junior Associate Brussels Webinar: The contraversial Bayer judgment and its potential impact on patent litigation in Europe Philippe Campolini, IP partner at Stibbe in Brussels, acts as panelist in a webinar organised by EPLAW (the European Patent Lawyers Association) on the contraversial Bayer judgment and its potential impact on patent litigation in Europe. Stibbe advises KBC Securities Stibbe assisted KBC Securities as underwriters on the IPO of ThromboGenics on Euronext Brussels. Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products. Stibbe advises on the contemplated IPO of Agendia Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products. Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency. Stibbe advises worldwide seeds leader Stibbe assisted a worldwide seeds leader in negotiations on cooperation deals with competitors. Stibbe advises pharmaceutical multinational Stibbe assisted a pharmaceutical multinational in complex litigations. Stibbe advises on the IPO of Tornier Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix. Stibbe advises European leading television format supplier Stibbe assisted a European leading television format supplier in various legal aspects of TV phone-in games. Mini-symposium “De accountant – Paard van Troje?” Op dinsdag 21 mei organiseert de afdeling Corporate Criminal Law & Investigations van Stibbe een mini-symposium rond het thema van de accountant als pseudo-opsporingsambtenaar en de controlecliënt als potentiële verdachte. Nieuwe wet op misbruik economische afhankelijkheid, onrechtmatige bedingen en oneerlijke marktpraktijken tussen ondernemingen Bij wet van 4 april 2019 heeft de Belgische wetgever drie reeksen van nieuwe praktijken gereglementeerd: Een verbod op misbruik van economische afhankelijkheid, een verbod op oneerlijke bedingen in B2B, en een verbod op oneerlijke marktpraktijken. Pagination Previous page Page 10 Current page 11 Page 12 Page 13 Next page
Stibbe advises Lundbeck Stibbe advised Lundbeck on the acquisition of Prexton Therapeutics BV for an amount of up to EUR 905 million.
Stibbe advises Aedifica Stibbe advised Aedifica on the acquisition of a healthcare residence for the elderly in Franeker (Friesland).
Stibbe advises SleepScore Labs Stibbe advised SleepScore Labs on the acquisition of Sleep.ai, a Netherlands-based digital health company.
Stibbe advises Aedifica Stibbe's Real Estate Transaction Group advised Aedifica NV, a Belgian listed company investing in healthcare real estate, on the further expansion of its portfolio in the Netherlands.
Webinar: The contraversial Bayer judgment and its potential impact on patent litigation in Europe Philippe Campolini, IP partner at Stibbe in Brussels, acts as panelist in a webinar organised by EPLAW (the European Patent Lawyers Association) on the contraversial Bayer judgment and its potential impact on patent litigation in Europe.
Stibbe advises KBC Securities Stibbe assisted KBC Securities as underwriters on the IPO of ThromboGenics on Euronext Brussels.
Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.
Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.
Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.
Stibbe advises worldwide seeds leader Stibbe assisted a worldwide seeds leader in negotiations on cooperation deals with competitors.
Stibbe advises pharmaceutical multinational Stibbe assisted a pharmaceutical multinational in complex litigations.
Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix.
Stibbe advises European leading television format supplier Stibbe assisted a European leading television format supplier in various legal aspects of TV phone-in games.
Mini-symposium “De accountant – Paard van Troje?” Op dinsdag 21 mei organiseert de afdeling Corporate Criminal Law & Investigations van Stibbe een mini-symposium rond het thema van de accountant als pseudo-opsporingsambtenaar en de controlecliënt als potentiële verdachte.
Nieuwe wet op misbruik economische afhankelijkheid, onrechtmatige bedingen en oneerlijke marktpraktijken tussen ondernemingen Bij wet van 4 april 2019 heeft de Belgische wetgever drie reeksen van nieuwe praktijken gereglementeerd: Een verbod op misbruik van economische afhankelijkheid, een verbod op oneerlijke bedingen in B2B, en een verbod op oneerlijke marktpraktijken.